Published in Biotech Law Weekly, August 5th, 2005
There are an estimated 2.5 million heart failure patients in Classes II, III and IV in the United States, 400,000 of whom are due each year, and 500,000 new heart failure patients are diagnosed annually. The treatment of heart failure is the largest single cost to Medicare, $40 billion per year.
Cardiomedics has requested that Medicare coverage of ECP for the treatment of heart failure be limited to the use of ECP devices...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.